IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Effects of Magnesium Supplementation on Vascular Structure and Function in Hypertensive Patients (MG600)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Introduction: Magnesium has been the target for many experimental and clinical studies due to the negative correlation between its serum and intracellular levels and the prevalence of hypertension and other cardiovascular diseases.
Objective: To evaluate the effects of magnesium supplementation in hypertensive patients who are under diuretic treatment, including correlation of clinical and nutritional parameters with structural and functional aspects of the macrocirculation.
Methods: A prospective, randomized, double blind, placebo controlled study will be performed in hypertensive patients, aged between 40 and 65 years-old, in regular use of thiazidic diuretic as antihypertensive monotherapy,. The patients will be divided in two main groups according to supplementation with placebo or magnesium chelate 300mg twice a day (total of 600mg magnesium element per day). Before and after 3 and 6 months of supplementation, the patients will be submitted to clinical and nutritional evaluation, biochemical analysis, including intracellular magnesium measurement, and study of the macrocirculation with ambulatory blood pressure monitoring, analysis of flow-mediated dilation of brachial artery, measurement of carotid intima-media thickness, and carotid-femoral and carotid-radial pulse wave velocity to estimate central and peripheral arterial stiffness.
Analysis: Data will be expressed as mean±epm. Statistical analysis will be performed using software Prism® (GraphPad, version 5.0). Continuous variables in each group will be compared using "t test", and P<0.05 will be considered statistically significant.
| Condition | Intervention | Phase |
|---|---|---|
| Hypertension Endothelial Dysfunction | Dietary Supplement: magnesium Dietary Supplement: placebo | Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Investigator) Primary Purpose: Supportive Care |
| Official Title: | Effects of Magnesium Supplementation on Vascular Structure and Function in Hypertensive Patients |
- Improvement of vascular function [ Time Frame: six months ]
- Improvement of vascular structure and blood pressure [ Time Frame: six months ]
| Enrollment: | 52 |
| Study Start Date: | March 2010 |
| Study Completion Date: | November 2012 |
| Primary Completion Date: | November 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Magnesium
Magnesium chelate 600 mg per day
|
Dietary Supplement: magnesium
Magnesium chelate, 300mg (2 capsules of 150mg) twice a day, per oral Total of 600mg per day
Other Name: Mg supplement
|
|
Placebo Comparator: Placebo
Placebo 4 capsules per day
|
Dietary Supplement: placebo
Two capsules of placebo per oral twice a day
Other Name: Inactive component
|
Detailed Description:
The main objective of this study is to evaluate whether magnesium supplementation is associated with improved blood pressure control and whether it has beneficial effects on the vascular structure and function in non-diabetic hypertensive patients who are receiving r diuretic therapy.
Patients will be evaluated in a prospective, randomized, double-blind study and will be admitted to the study if they reach all the inclusion criteria and no exclusion criteria.
In this study, magnesium chelate was chosen because of its better absorption rate. The dosages are different in many protocols but in this project the patients will receive 600 mg of magnesium element daily divided in 300 mg twice a day. The patients will be divided in two main groups according to supplementation with placebo or magnesium chelate 300mg twice a day (total of 600mg magnesium element per day). Before and after 3 and 6 months of supplementation, the patients will be submitted to clinical and nutritional evaluation, biochemical analysis, including intracellular magnesium measurement, and study of the macrocirculation with ambulatory blood pressure monitoring, analysis of flow-mediated dilation of brachial artery, measurement of carotid intima-media thickness, and carotid-femoral and carotid-radial pulse wave velocity to estimate central and peripheral arterial stiffness.
Eligibility| Ages Eligible for Study: | 40 Years to 65 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Women aged between 40 and 65 years-old
-
Hypertension with mild blood pressure elevation:
- Systolic BP between 140 and 159mmHg AND/OR
- Diastolic BP between 90 and 99 mmHg
- Antihypertensive monotherapy with daily use of thiazidic diuretic, at least in the last 30 days
- Signature of the Informed Consent by the patient or his legal representative
Exclusion Criteria:
- Evidences for secondary hypertension
- Hypertension in stage 2, SBP ≥ 160mmHg and/or DBP ≥ 100mmHg, before the beginning of supplementation
- Blood pressure > 180 x 100 mmHg in any phase of the study
- Body mass index > 35 kg/m2
- Diabetes Mellitus
- Renal disease presenting glomerular filtration rate < 60ml/min
- Coronary artery disease clinically evident with previous episode of myocardial infarction and/or myocardial revascularization
- Clinical signs of heart failure
- History of stroke
- Any condition, disease or therapy that, under investigator's opinion, may influence objectives, results, or put in risk the safety of the patients.
- Pregnancy
- Patients should not be taking any mineral or vitamin supplements
- Gastrointestinal conditions
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT01151683
| Brazil | |
| Department of Clinical Medicine, State University of Rio de Janeiro | |
| Rio de Janeiro, RJ, Brazil, 20551030 | |
| Principal Investigator: | Mario F Neves, MD, PhD | State University of Rio de Janeiro |
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Mario Fritsch Neves, Full Professor, Rio de Janeiro State University |
| ClinicalTrials.gov Identifier: | NCT01151683 History of Changes |
| Other Study ID Numbers: |
MG600 |
| Study First Received: | June 25, 2010 |
| Last Updated: | January 4, 2013 |
Keywords provided by Mario Fritsch Neves, Rio de Janeiro State University:
|
hypertension endothelial dysfunction |
Additional relevant MeSH terms:
|
Hypertension Vascular Diseases Cardiovascular Diseases |
ClinicalTrials.gov processed this record on July 26, 2017